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Abstract
Background: Postprocedural atrial extrasystole (AES) frequency predicts atrial fibril-
lation (AF) recurrence after pulmonary vein isolation (PVI) in patients with paroxys-
mal AF. However, the predictive value of preprocedural AES frequency is unknown. 
We investigate whether preprocedural AES frequency is a feasible marker to predict 
(timing of) AF recurrence after PVI.
Methods: Patients (N = 684) with paroxysmal or persistent AF undergoing first-time 
PVI were evaluated for (a) the frequency of AES/day on Holter recordings without 
AF prior to PVI, (b) AF episodes during the 90 days blanking period, and (c) AF recur-
rences afterward. The correlation between AES/day and both development and tim-
ing of AF recurrences was tested.
Results: Preprocedural AES/day was similar in patients with paroxysmal (66 [20-295] 
AES/day) and persistent AF (115 [12-248] AES/day, P = .915). During the blanking pe-
riod, 302 (44.2%) patients showed AF episodes. AF recurred in 379 (55.4%) patients 
at 203 (105-400) days after PVI. AF recurred more frequently in patients with persis-
tent (N = 104 [69.3%]) than in patients with paroxysmal AF (N = 275 [51.5%], P < .001). 
Frequency of AES prior to PVI was not correlated with development (P = .203) or 
timing (P = .478) of AF recurrences. AF recurrences occurred both more frequently 
(P < .001) and earlier (P < .000) in patients with AF during the blanking period.
Conclusion: AES/day prior to PVI is not correlated with (timing of) AF during the 
blanking period or AF recurrences, and is therefore not a feasible marker for AF re-
currences in patients with PAF. AF during the blanking period is correlated with AF 
recurrence.
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1  | INTRODUC TION
Atrial fibrillation (AF) is often triggered by atrial extrasystoles (AES), 
originating from the pulmonary vein (PV) area.1 Isolation of these trig-
gers, by means of creating circular lesions around the PVs, is a potential 
curative treatment modality for AF. Reported 1-year AF-free survival 
rates after PV isolation (PVI) vary from 50% to 81%.2 AF recurs more 
frequently in patients with persistent AF (PeAF) than in patients with 
paroxysmal AF (PAF).3 It is generally assumed that in the former group, 
AF is mediated by an arrhythmogenic substrate, rather than by trig-
gers. Identification of individual patients at risk for AF recurrences 
remains challenging. Clinical markers associated with AF recurrence 
include atrial dilatation, valvular heart disease, and type of AF.4
The value of daily AES frequency after PVI for AF recurrences has 
been investigated previously in patients with PAF.5,6 However, it is 
unknown whether AES frequency prior to PVI is a feasible marker to 
predict AF recurrence after PVI. Advanced atrial remodeling, caused 
by, for example, AF, might result in increased AES frequency.7 If AES 
prior to PVI were to result from non-PV foci, this could relate to AF 
recurrence after PVI. Since remodeled patients are also more prone 
to develop recurrences,3 AES frequency prior to PVI could be a non-
invasive clinical marker that allows identification of subjects with a 
high risk for nonsuccessful PVI outcome.
Hence, AES frequency prior to PVI potentially allow early rec-
ognition of patients at risk for AF recurrence. Subsequently, this 
marker might be used to tailor treatment of AF to the individual 
patient. The aim of the current study was therefore to investigate 
whether AES frequency prior to PVI is associated with (timing of) 
development of AF in the blanking period and (timing of) AF recur-
rence during long-term follow-up, not only in patients with PAF 
but also PeAF.
2  | METHODS
This retrospective, observational study is part of the “Arrhythmias 
predicted by ExtraSystoles” (AES) study. The study was approved 
by the institutional medical ethical committee (MEC-2016-062) and 
complies to the Declaration of Helsinki. Written informed consent 
was not obliged.
Patients undergoing first-time radiofrequency or cryoballoon 
PVI for drug-resistant PAF or PeAF in the Erasmus MC between 
2004 and August 2015, with ≥1 Holter recording prior to or after 
ablation were evaluated. Exclusion criteria included longstanding 
PeAF or the absence of Holter registrations. The follow-up period 
extended until the end of July 2016. Clinical data were obtained 
from the electronic patient files.
Beta-blockers or other anti-arrhythmic agents were not with-
held prior to PVI. Drugs were continued during the first 3 months 
and thereafter discontinued to discretion of the electrophysiologist.
Patients underwent an endovascular PVI by means of radiofre-
quency or cryoballoon ablation. Catheter manipulation was either 
manual or remotely controlled. In case of radiofrequency ablation, 
catheter navigation was supported by electroanatomical mapping. 
Immediate procedural success was defined as the presence of an exit 
block.
All postprocedural rhythms from various rhythm recording de-
vices, such as 12-lead surface ECG, continuous Holter registration, 
and implantable loop recorders, were evaluated for the presence of 
AF.8,9 The amount of AES on Holter recordings was standardized per 
24 hours (AES/day). Since AES do not occur during AF episodes, Holter 
recordings with AF (either paroxysms or continuous) were not included 
for these calculations. A total AES count could not be retrieved in 13 
patients. We defined AF recurrences according to the latest guide-
lines, hence any documented AF episode after the blanking period.8,9 
Consequently, AF episodes within the 90 days blanking period were 
not considered AF recurrences. The study endpoint was AF recurrence.
All data were tested for normality. Normally distributed, con-
tinuous data are expressed as mean ± standard deviation, whereas 
dichotomous variables are depicted as number (percentage). 
Comparison of these data was performed using, respectively, 
Students t test and χ2 test. Nonparametric tests (including Kruskal-
Wallis and Mann-Whitney U tests) were applied for comparison of 
continuous, skewed data, which are presented as median (interquar-
tile range). Wilcoxon signed-rank test was performed to compare 
two related samples of continuous, skewed variables. Spearman's 
rank (ρ) was applied to test the correlation between non-normally 
distributed continuous variables and/or categorical parameters. 
Since the amount of AES/day calculated from baseline Holter re-
cordings is non-normally distributed, data in the amount of AES/day 
calculated from baseline Holter recordings, patients were catego-
rized into quartiles of AES/day, to evaluate its effect on AF recur-
rences. AF-free survival after PVI in various patient categories was 
studied with Kaplan-Meier curves and log-rank testing. A P-value of 
.05 was considered statistically significant.
3  | RESULTS
The total study population consisted of 684 patients (486 [71.1%] 
males). Clinical baseline characteristics of all patients are depicted 
in Table 1. The majority of patients underwent cryoballoon ablation 
(N = 396, 57.9%). In 288 patients (42.1%), ablation was performed 
with radiofrequency energy, either manually (N = 211) or with mag-
netic (N = 47) or robotic (N = 30) navigation systems. AF was paroxys-
mal in 534 patients (78.1%), the remaining 150 patients (21.9%) had 
PeAF. Prior to PVI, ≥1 anti-arrhythmic drugs were used by 368 (93.3%) 
patients, as shown in Table 1. Successful isolation of the PVs (criteria 
according to the recent AF guidelines)8,9 was achieved in all patients.
Electrophysiological parameters of all Holter recordings are 
summarized in Table 2. Holter recordings were performed 118 
(65-193) days prior to PVI. In 261 (43.6%) patients, the Holter re-
cordings showed either paroxysms or continuous AF: 140 (53.6%) 
and 121 (46.4%) recordings, respectively. In 326 Holter record-
ings without AF episodes, a median frequency of 66 (20-295) AES/
day was observed on Holter recordings prior to PVI of patients 
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with PAF (N = 288), whereas patients with PeAF (N = 38) had 115 
(12-248) AES/day (P = .915). The AES/day frequency was not cor-
related with anti-arrhythmic drug usage (all classes and digoxin 
P > .05).
The amount of AES/day weakly correlated with age (ρ = 0.266, 
P < .001), gender (ρ = −0.137, P = .014), left atrial volume (ρ = 0.212, 
P = .006), and diabetes (ρ = 0.132, P = .017). There was no correlation 
between AES/day and time since AF diagnosis, type of AF prior to 
PVI or left ventricular function, or anti-arrhythmic drug usage (all 
P > .05). In addition, none of the other known (cardiac) risk factors 
including BMI, hypertension, hyperlipidemia, and thyroid disease 
correlated with AES/day (all P > .5).
AF during the blanking period occurred in 302 patients (44.2%), 
which is depicted in the flowchart in Figure 1. Clinical variables 
including gender, age, body mass index, hypertension, diabetes mel-
litus, hyperlipidemia, anti-arrhythmic drug usage, and left ventricu-
lar function were not correlated with AF during the blanking period. 
However, thyroid disease (ρ = 0.105; P = .006) and type of AF (ρ = 0.084; 
P = .028) correlated (weakly) with AF during the blanking period. First 
AF episodes were documented 7.0 (2.0-20.0) days after the procedure. 
Incidence was higher in patients with PeAF (N = 78, 52.0%) than PAF 
(N = 224, 41.9%) prior to PVI (P = .028). There was no difference in 
the moment of the first AF episode between patients with PAF and 
TA B L E  1   Baseline characteristics
 Overall (N = 684)
Age (y) 57.8 ± 9.7
Gender (male, N [%]) 486 (71.1)
Type AF (N, [%])
Paroxysmal 534 (78.1)
Persistent 150 (21.9)
Time since diagnosis (y) 3.0 (1.0-6.5)
Type PVI
Cryoballoon 396 (57.9)
Radiofrequency 288 (42.1)
Echocardiography
Left atrial volume index (mL/m2) 40.8 ± 13.3
Left ventricular function (N, [%])
Normala 570 (83.3)
Mild impairmentb 92 (13.5)
Moderate impairmentc 20 (2.9)
Severe impairmentd 2 (0.3)
Anti-arrhythmic drug usage
Class I 259 (37.9)
Class II 288 (42.1)
Class III 312 (45.6)
Class IV 50 (7.3)
Cardiovascular risk factors
Hypertension (N, [%]) 260 (38.0)
Hyperlipidemia (N, [%]) 96 (14.0)
Diabetes mellitus (N, [%]) 48 (7.0)
Thyroid disease (N, [%]) 55 (8.0)
Body mass index (kg/m2) 27.2 ± 4.1
Abbreviations: AF, atrial fibrillation; BSA, body surface area; PVI, 
pulmonary vein isolation.
aEjection fraction >50% 
bEjection fraction 40%–50% 
cEjection fraction 30%–40% 
dEjection fraction <30% 
TA B L E  2   Holter registrations
 
Prior to PVI 
(N = 599)
Average heart rate (bpm) 69 (61-80)
AF on Holter (N, %) 261 (43.6)
Paroxysmal AF 172 (32.2)
Paroxysms 126 (23.6)
Continuous 46 (8.6)
Persistent AF 89 (59.3)
Paroxysms 14 (9.3)
Continuous 75 (50.0)
AES/day (N) 68 (18-289)
Paroxysmal AF N = 288
66 (20-295)
Persistent AF N = 38
115 (12-248)
Abbreviations: AES, atrial extrasystole; AF, atrial fibrillation; Bpm, beats 
per minute; PVI, pulmonary vein isolation.
F I G U R E  1   AF recurrence after first-time PVI. Flowchart 
illustrating the amount of patients with AF recurrences per type 
of AF prior to PVI and for patients with and without AF during the 
90 day blanking period. AF, atrial fibrillation; PAF, paroxysmal atrial 
fibrillation; PeAF, persistent atrial fibrillation; PVI, pulmonary vein 
isolation
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PeAF: 8 (2-22) vs 5 (2-15) days after procedure (P = .092). The incidence 
of AES/day prior to PVI was not associated with the presence of AF 
episodes in the blanking period for both patients with PAF (P = .374) 
and PeAF (P = .053). Also, AES/day prior to PVI did not correlate with 
timing of AF episodes during the blanking period, in patients with PAF 
(P = .274) and patients with PeAF (P = .422).
Median follow-up time after PVI was 604 (177-1822) days. 
Overall, AF recurred after the blanking period in 55.4% of the pop-
ulation (N = 379) at 203 (105-400) days after the procedure. The 
flowchart in Figure 1 shows the number of patients with AF episodes 
during the blanking period and AF recurrences for patients with par-
oxysmal or persistent AF separately. Furthermore, Figure 2 shows 
the fluctuations in the rhythm outcome per year of procedure for the 
overall study population (P = .003).
As illustrated in Figure 3, AF recurred more frequently in pa-
tients with PeAF (N = 104 [69.3%]) than in patients with PAF 
(N = 275 [51.5%], P < .001). The majority of recurrences was ob-
served in the first year after PVI and timing of first AF recurrence 
was similar in both patient groups: 168 (102-355) vs 213 (107-419) 
days (P = .112). In 218 (31.8%) patients, at least one redo PVI was 
performed. Reconduction of 543 PVs was observed in 196 (92.9%) 
patients undergoing redo ablation and occurred equally frequent in 
patients with PAF or PeAF (P = .886) and equally frequent after cryo-
balloon or radiofrequency ablation (P = .877). AF recurrence was not 
correlated with anti-arrhythmic drug usage at baseline.
Kaplan-Meier curves in Figure 4 show the AF-free survival for 
patients with PAF or PeAF prior to PVI with (solid lines) and without 
(dashed lines) AF during the blanking period separately. AF recurred 
more frequently in patients with (N = 230, 76.2%), than in patients 
without AF during the blanking period (N = 149, 39.0%; P < .001). The 
curves also show that AF recurrences occurred earlier in both patients 
with PAF and PeAF with AF during the blanking period (P < .001).
Overall, AES/day prior to PVI was not correlated with AF recur-
rence and time to first recurrence: ρ = 0.071, P = .203 and ρ = −0.055, 
P = .478. The left panel of Figure 5 shows that AF recurrences in pa-
tients with paroxysmal AF prior to PVI occur equally in all four quartiles 
of AES/day. The right panel depicts AF-free survival for patients with 
persistent AF. In both patient groups, AES/day prior to PVI did not cor-
relate with either AF recurrence or time to recurrence (Table 3).
4  | DISCUSSION
The present study demonstrates that AES/day prior to PVI is not 
correlated with (timing of) AF in the blanking period or with (tim-
ing of) AF recurrence in PAF. As expected, AF recurrences are more 
F I G U R E  2   AF recurrence per year. Proportion of patients with 
AF recurrences (red) or without AF recurrences (green) after first-
time pulmonary vein isolation, for each year separately. AF, atrial 
fibrillation
F I G U R E  3   AF-free survival per type AF. Freedom from AF 
recurrences for patients with PAF (blue line) and PeAF (red line) 
during long-term follow-up. 90 day blanking period is indicated in 
grey. AF, atrial fibrillation; PAF, paroxysmal AF; PeAF, persistent 
AF; PVI, pulmonary vein isolation
F I G U R E  4   Effect of AF during the blanking period on AF-free 
survival. Dashed blue line: patients with PAF prior to PVI, without 
AF during the blanking period (PAF-). Solid blue line: patients 
with PAF prior to PVI, with AF during the blanking period (PAF+). 
Dashed red line: patients with PeAF prior to PVI, without AF during 
the blanking period (PeAF-). Solid red line: patients with PeAF prior 
to PVI, with AF during the blanking period (PeAF+). 90 day blanking 
period is indicated in grey. AF, atrial fibrillation; PAF, paroxysmal 
AF; PeAF, persistent AF; PVI, pulmonary vein isolation; −, no AF 
during blanking period; +, AF during blanking period
     |  5LANTERS ET AL.
frequent in patients with PeAF than with PAF. As an incidental find-
ing, we showed that development of AF in the blanking period was 
correlated with AF recurrence afterward.
The predictive value of AES for development of new-onset AF 
has been widely studied.10‒12 In a large cohort of 1,357 patients 
with various underlying diseases, Acharya et al12 demonstrated that 
patients with ≥100 AES/day have a higher risk for development of 
new-onset AF (HR 2.97). Recently, this was also confirmed for pa-
tients with congenital heart disease.11 The predictive value of AES 
for development of AF recurrences was mainly examined after PVI 
in patients with PAF,5,6 whereas the present study evaluates the 
value of AES prior to PVI in both PAF and PeAF patients. Gang et al5 
showed in a prospective study in 220 patients with PAF that ≥142 
AES/day on the 6 months Holter recording was associated with a 
higher risk of AF recurrences after PVI (HR 2.84). However, the re-
lation between AES prior to PVI and the long-term AF-free survival 
after PVI was not yet described. In this era of patient-tailored med-
icine, a more accurate estimation of the expected procedural out-
come is desired for selecting the optimal strategy for each individual 
patient. Therefore, we examined whether a higher incidence of AES 
prior to PVI is associated with AF recurrences. Since this was not 
the case, it is most likely not a feasible marker in clinical practice. 
Although it is generally assumed that AES in patients with AF mainly 
originate from the PV area, other origins, for example, the supe-
rior vena cava, have also been described.1,13,14 After PVI, AES can 
either result from non-PV foci or from, for example, reconduction 
of the initially isolated PVs. In case these AES initiate AF episodes, 
additional ablation of these non-PVI foci could potentially cure AF 
in these patients. The group of Lin et al14 showed that acute success 
rates of ablation of these foci were highly variable and depend on 
the origin of ectopy, for example, superior vena cava (96%, N = 27), 
posterior free wall of the left atrium (63%, N = 5, crista termina-
lis [100%, N = 10] and interatrial septum [0%, N = 1]). During long-
term follow-up, AF recurred in 36.8% (N = 25) patients.14 At present, 
additional ablation of non-PV foci (if reproducible) is included as a 
Class IIa recommendation in clinical guidelines on management of 
F I G U R E  5   AF-free survival per quartile AES prior to PVI. Left panel: freedom from AF recurrences after PVI for paroxysmal AF, patients 
are categorized according to the number of AES/day at Holter recordings prior to PVI. Blue line: Q1 ≤20 ES/day. Red line: Q2 = 20-66 AES/
day. Green line: Q3 = 66-295 AES/day. Yellow line: Q4 ≥295 AES/day. Right panel: freedom from AF recurrences after PVI for persistent 
AF, patients are categorized according to the number of AES/day prior to PVI. Blue line: Q1 ≤12 AES/day. Red line: Q2 = 12-115 AES/day. 
Green line: Q3 = 115-248 AES/day. Yellow line: Q4 ≥248 AES/day. 90 day blanking period is indicated in grey. AF, atrial fibrillation; AES, atrial 
extrasystole; PVI, pulmonary vein isolation
TA B L E  3   AES frequency and AF recurrence
 
AES/day prior to 
PVI
Quartile AES prior 
to PVI
Paroxysmal AF
AF during 
blanking period
ρ = 0.053; P = .374 ρ = 0.045; P = .448
Time to AF during 
blanking period
ρ = 0.107; P = .274 ρ = 0.058; P = .552
AF recurrence ρ = 0.073; P = .215 ρ = 0.062; P = .293
Time to AF 
recurrence
ρ = −0.047; P = .574 τ = −0.032; P = .702
Persistent AF
AF during 
blanking period
ρ = 0.316; P = .053 ρ = 0.282; P = .086
Time to AF during 
blanking period
ρ = 0.244; P = .422 ρ = 0.285; P = .345
AF recurrence ρ = 0.058; P = .729 ρ = 0.078; P = .640
Time to AF 
recurrence
ρ = −0.182; P = .385 ρ = −0.145; P = .490
Abbreviations: AES, atrial extrasystole; AF, atrial fibrillation; PVI, 
pulmonary vein isolation.
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patients with AF. In the present study, AF also recurred in the ab-
sence of PV reconduction. This suggests that AES initiating AF are 
most likely generated by non-PV foci. Besides the above mentioned 
non-PV foci, AES might also be generated by other atrial areas. It is 
generally accepted that AF episodes induce structural and electrical 
remodeling of the atria.15,16 As a result, cardiomyocyte hypertrophy, 
fibroblast proliferation, and deposition of extracellular matrix lead to 
separation of adjacent bundles of cardiomyocytes and subsequently 
conduction block.17 Redistribution of cell-cell connexins and down-
regulation of ion channels also cause impaired conduction.18 Next 
to these conduction abnormalities, coupling of myofibroblast and 
cardiomyocytes also facilitates induction of spontaneous ectopic 
activity.7 An intracellular calcium overload, caused by atrial stress, 
may provoke delayed afterdepolarizations, which in turn can pro-
duce triggered activity. Altogether, this suggests that (micro)reentry 
and/or ectopic activity are more likely to occur in remodeled atria, 
which in turn may lead to an increased number of AES.
A 90 days blanking period after PVI is recommended in both 
European and American guidelines.8,9 AF episodes within this 
window may result from postprocedural inflammation, edema, or 
recovery phase. Arrhythmias in the blanking period would there-
fore be nonspecific and not directly related to treatment failure. 
Nonetheless, episodes of AF or other arrhythmias during this blank-
ing period are frequently reported.19 In a recent study, Willems et 
al,20 examined the value of the 90 days blanking period in 401 pa-
tients undergoing first-time PVI for PAF. They show that 1-year free-
dom from any AT decreased significantly to 28.7% if AF occurred 
during the blanking period, which was the case in 49.1% of the pop-
ulation. Also, timing of latest symptomatic AT was correlated with 
time to AF recurrence.20 The present study confirms the decrease 
in AF-free survival in patients with not only PAF but also PeAF who 
have AF during the blanking period. Other AT were not included. In 
addition, a similar pattern is observed in patients with PeAF.
As a result from the retrospective study design, not all Holter 
recordings prior to and after PVI were available. Most patients used 
anti-arrhythmic drugs, this might have influenced AES/day, although 
there was no difference in the amount of AES in patients with or 
without anti-arrhythmic drugs, and correlations between AES/day 
and drug usage were lacking. Asymptomatic and/or short-lasting 
AF paroxysms might be missed if the patient was not connected to 
rhythm monitoring devices. AES frequency can vary from day to day 
and is influenced by, for example, autonomic tone and physical ac-
tivity. Prolonged recordings might give a more accurate reflection 
of the AES frequency. For optimal comparison of AES/day between 
the different types of AF, a larger number of Holter recordings from 
PeAF patients is most likely required. Origin of AES could not be 
determined using 3-lead Holter registrations.
5  | CONCLUSION
The amount of AES/day prior to PVI is not correlated with (tim-
ing of) AF episodes in the blanking period, or with (timing of) AF 
recurrences and is therefore not suitable as a biomarker to identify 
PAF patients at risk for AF recurrences. However, patients with AF 
episodes during the blanking period develop AF recurrences earlier 
than patients without early AF episodes.
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